BioAscent spending £1M to boost drug discovery service offering

By Chris Newmarker | September 14, 2020

BioAscent (Newhouse, U.K.) recently announced that it will spend £1 million ($1.3 million) on new instrumentation and equipment.

The investment is meant to further enhance the company’s offerings in integrated drug discovery and compound management.

The new instrumentation will include a FLIPR Penta screening system and a Biacore 8k Surface Plasmon Resonance (SPR) system, as well as a new workstation for plate set-up during compound management, and updated IT infrastructure.

“We have the experience and expertise in the team to support a wide range of drug discovery projects, and we are committed to delivering the highest quality research, cost-effectively for our clients. Our investment in new systems and ensuring that the team has the best instrumentation at their disposal is a reflection of this commitment,” BioAscent CEO Paul Smith said in a Sept. 3 news release.

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.